Literature DB >> 11455588

Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth.

R I Yarden1, M A Wilson, S A Chrysogelos.   

Abstract

Epidermal growth factor receptor (EGFR) is a transmembrane receptor whose overexpression in breast cancer predicts for poor prognosis and is inversely correlated with expression of estrogen receptor (ER). This study was designed to investigate whether estrogen plays an active role in suppression of EGFR expression in estrogen-responsive breast cancer cell lines expressing low levels of EGFR. Upon withdrawal of estrogen, EGFR mRNA and protein increased 3-6 fold in MCF-7, T47D, and BT474 ER+ breast cancer cells. This was reversible upon addition of estradiol back to the culture media, but only after prolonged treatment. Nuclear run-on assays and studies with the transcription inhibitor actinomycin D demonstrated that regulation is at the transcriptional level. These results indicate that in the presence of estrogen, ER+ breast cancer cells possess active mechanisms to suppress EGFR expression. Up-regulation of EGFR in response to estrogen depletion and growth inhibition could represent an attempt to rescue cell growth by utilizing an alternative pathway. Indeed, we found that estrogen-depleted breast cancer cells are more sensitive to the mitogenic effects of EGF and TGF-alpha, and simultaneous blockade of both estrogen and EGFR signaling pathways induced cell death. J. Cell. Biochem. Suppl. 36: 232-246, 2001. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455588     DOI: 10.1002/jcb.1142

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  31 in total

1.  Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208.

Authors:  Xi-wei Ji; Guang-ping Chen; Yan Song; Ming Hua; Li-jie Wang; Liang Li; Yin Yuan; Si-yuan Wang; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

Review 2.  Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.

Authors:  Mario Giuliano; Meghana V Trivedi; Rachel Schiff
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

3.  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.

Authors:  Lisa M Arendt; Teresa A Rose-Hellekant; Eric P Sandgren; Linda A Schuler
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 4.  Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

Authors:  Andrea Milani; Elena Geuna; Gloria Mittica; Giorgio Valabrega
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 5.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

6.  Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Authors:  Guangliang Li; Jing Zhang; Ketao Jin; Kuifeng He; Yi Zheng; Xin Xu; Haohao Wang; Haiyong Wang; Zhongqi Li; Xiongfei Yu; Xiaodong Teng; Jiang Cao; Lisong Teng
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

Review 7.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

Review 8.  Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.

Authors:  Priscilla Merriam; William M Sikov
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-10-26

9.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

10.  In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin.

Authors:  Zoë Davison; Carol Dutkowski; Julia M W Gee; Robert I Nicholson; Charles M Heard
Journal:  Pharm Res       Date:  2008-07-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.